60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)

Revenue Financials Chart

Previous Close

$1.26

52W Range

$0.70 - $18.36

50D Avg

$1.09

200D Avg

$2.14

Market Cap

$2.67M

Avg Vol (3M)

$288.67K

Beta

5.27

Div Yield

-

SXTP Company Profile

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Jul 12, 2023

Website

SXTP Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Sep 24	Jun 24	Mar 24
Product	$135.29K	$124.97K	-
Service	$10.79K	$10.79K	$10.79K

Fiscal year ends in Dec 23 | Currency in USD

SXTP Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$253.57K	$223.21K	$1.16M
Operating Income	$-5.15M	$-1.75M	$-1.12M
Net Income	$-3.70M	$-6.18M	$-4.25M
EBITDA	$-5.05M	$-1.71M	$-1.01M
Basic EPS	$-0.64	$-1.07	$-0.74
Diluted EPS	$-0.64	$-1.07	$-0.74

Fiscal year ends in Dec 23 | Currency in USD